Treatment with the SGLT2 inhibitor canagliflozin is associated with a reduced risk for anemia-related outcomes among people with type 2 diabetes and chronic kidney disease, suggests a post-hoc analysis of the CREDENCE trial.
Younger age at onset of type 2 diabetes is associated with a significantly increased risk for cardiovascular death, as well as an increased likelihood of having offspring who will also develop diabetes, Framingham Heart Study data show.
The selective mineralocorticoid receptor antagonist finerenone significantly reduces the risk for progression of chronic kidney disease and for cardiovascular events in people with type 2 diabetes, show the FIDELIO-DKD findings.
Results from an observational study suggest that the use of metformin in older patients with type 2 diabetes is associated with a reduced decline in both global cognition and executive function, and a decreased risk for dementia.
Research shows moderate or severe diabetic ketoacidosis is associated with lower IQ and reduced short- and long-term memory in children with type 1 diabetes, with some impairment seen even in newly diagnosed children.
Bariatric surgery is associated with a reduced prevalence of pancreatic cancer in obese individuals with type 2 diabetes, suggest findings from a population-based study presented at UEG Week Virtual 2020.
Duodenal mucosal resurfacing combined with glucagon-like peptide-1 receptor agonists could enable some people with type 2 diabetes to discontinue insulin therapy, suggest findings from the pilot INSPIRE study.
Secondary analysis of the VERTIS CV trial supports a significant protective effect of ertugliflozin on risk for heart failure in people with type 2 diabetes, despite the overall neutral outcome of the trial.
Real-world data suggest that the SGLT2 inhibitor empagliflozin is associated with estimated glomerular ﬁltration rate preservation, weight loss, and a reduced risk for major adverse kidney events when compared with other antihyperglycemics among people with type 2 diabetes.
The benefits of treatment with SGLT2 inhibitors are not negated by the initial decline in estimated glomerular filtration rate commonly seen with these drugs, show post-hoc analyses of the EMPA-REG OUTCOME and CREDENCE trials.
Absolute mortality rates are falling among younger people with type 1 diabetes, but excess mortality relative to the general population remains high and unchanged, show Scottish national registry data presented at the virtual 56th EASD Annual Meeting.
A device that clips onto an insulin pen can guide people with type 1 diabetes to more effectively rotate their injection site, resulting in less lipohypertrophy and glycemic variability, show the results of a proof-of-concept study.